Subscribe to our Newsletters !!

    Kumar Jeetendra

    Coronavirus immunization conceivable in mid 2021, says European office

    An immunization to counter the new coronavirus could be affirmed in about a year in an “idealistic” situation, an office which supports meds for the European Union said on Thursday. The European Medicines Agency, in correspondence with 33 engineers, was doing everything it could to accelerate the endorsement procedure, the EMA’s head of immunizations, Marco

    Specialists create Bluetooth-empowered thermometer with area sharing element

    The coronavirus pandemic is giving route for a ton of new creations, including foot-worked handwash machines. On comparative lines, a group of scientists in Chennai’s National Hub for Healthcare Instrumentation Development (NHHID) have built up a Bluetooth-empowered thermometer. Notwithstanding following fever, the thermometer can likewise speak with a cell phone application and offer the area.

    NovaLead Pharma to conduct Phase 3 trial for its discovery for COVID-19

    NovaLead Pharma, the Pune based pioneer in the field of drug repurposing in India has announced that it has received ‘in principal’ clinical trial permission with DCG(I) for its Repurposed Drug discovery to treat moderate COVID-19. This approved drug codenamed NLP21 is in human use for several years for its original use without any side

    Unichem Laboratories gets EIR from USFDA for Roha API unit

    Unichem Laboratories Limited has gotten the Establishment Inspection Report (EIR) from United Stated Food and Drug Administration (USFDA) on May 13, 2020 for our Active Pharmaceutical Ingredients (APIs) office at Roha. The United States Food and Drug Administration (USFDA) directed the assessment of our Roha office from seventeenth to 21st February 2020. Portions of UNICHEM

    The race to convey COVID-19 contact following applications

    Technologists and healthcare authorities around the globe are dashing to create cell phone applications to follow who has been in contact with transporters of the novel coronavirus. Contact-following, a malady control strategy that customarily depends on patients’ recollections of their developments, distinguishes individuals they may have contaminated so they also can be separated. Original applications

    Should sprinters wear a face veil outside?

    Should sprinters wear a face cover outside? It depends. You won’t generally need a face covering while at the same time running or riding a bicycle in case you’re practicing with nobody around, however it’s acceptable to convey one in the event that something goes wrong. The US Centers for Disease Control and Prevention suggests

    Sanofi says COVID-19 antibody will be accessible overall at the same time

    Sanofi will guarantee that a potential antibody against COVID-19, whenever affirmed, arrives at all locales of the world simultaneously, the administrator of the French drugmaker said on Thursday. “There will be no specific development given to any nation,” Serge Weinberg disclosed to France 2 TV. “We are sorted out with a few assembling units. Some

    China taking US look into on COVID-19: Mike Pompeo

    US Secretary of State Mike Pompeo on Thursday blamed China for “taking” US protected innovation and information identified with COVID-19 research. Pompeo’s charges came a day after the FBI and the Department of Homeland Security asserted that associations directing investigation into COVID-19 might be focused by PC programmers connected to the Chinese government. “The US

    Azithromycin and Hydroxychloroquine : Clinical trial begins in US

    A clinical preliminary has started in the US to assess whether the counter jungle fever sedate hydroxychloroquine, given along with the anti-toxin azithromycin, can forestall COVID-19 hospitalization and demise, as per the National Institutes of Health (NIH). Hydroxychloroquine is endorsed by the US Food and Drug Administration (FDA) to forestall and treat jungle fever, just

    Cipla announces its Q4 FY20 results demonstrating sustained growth momentum across core businesses and unlocking of respiratory pipeline

    Mumbai, May 15, 2020: Cipla Limited (BSE: 500087, NSE: CIPLA) today announced its audited consolidated financial results for quarter ended March 31st, 2020. Key highlights of the quarter: India: The Rx business grew by 12% on a y-o-y basis recording a 3rd consecutive quarter of market beating growth. The trade Gx business revives strongly recording